We carefully read the article by Cantini et al. [
[1]
]. This is an interesting study that evaluated the association between statin use
and clinical outcomes of programmed cell death 1 (PD-1) use using a prospective database.
If statins improve clinical outcomes in patients treated with PD-1 inhibitors, treatment
strategies for malignant pleural mesothelioma (MPM) and advanced non-small cell lung
cancer (aNSCLC) will dramatically change. Furthermore, this study suggests that those
who do not take statins may have a worse overall survival after the use of PD-1 inhibitors
for both MPM and aNSCLC, highlighting the importance of pre-treatment cardiovascular
risk assessment before treatment with PD-1 inhibitors. While interesting and informative,
we have some concerns regarding the study design.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.Eur J Canc. 2021; 144: 41-48https://doi.org/10.1016/j.ejca.2020.10.031
- Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2017; 28 (1): iv1-iv21https://doi.org/10.1093/annonc/mdx222
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2018; 29: iv192-iv237https://doi.org/10.1093/annonc/mdy275
- Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future.Front Oncol. 2020; 9: 1519https://doi.org/10.3389/fonc.2019.01519
- Different growth patterns of non-small cell lung cancer represent distinct biologic subtypes.Ann Thorac Surg. 2008; 85: 395-405https://doi.org/10.1016/j.athoracsur.2007.08.054
- Radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials: consensus statement from the NCI thoracic malignancy steering committee–International Association for The Study of Lung Cancer–mesothelioma applied research foundation clinical trials planning meeting.J Thorac Oncol. 2019; 14: 1718-1731https://doi.org/10.1016/j.jtho.2019.08.012
- Confounding.Nephron Clin Pract. 2010; 116: c143-c147https://doi.org/10.1159/000315883
Article info
Publication history
Published online: May 22, 2021
Accepted:
March 12,
2021
Received:
March 10,
2021
Identification
Copyright
© 2021 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patientsEuropean Journal of CancerVol. 144
- Re: Comments on ‘High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non–small cell lung cancer patients’European Journal of CancerVol. 153
- PreviewWe thank Dr Akio Hara and Prof. Takashi Yoshioka and colleagues for their interest and comments on our study investigating the association between high-intensity statins and clinical outcome in malignant pleural mesothelioma (MPM) and advanced non–small cell lung cancer (aNSCLC) patients treated with programmed cell death protein 1 (PD-1) inhibitors [1].
- Full-Text
- Preview
